Eli Lilly (LLY)
(Delayed Data from NYSE)
$806.06 USD
-0.08 (-0.01%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$806.06 USD
-0.08 (-0.01%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab
by Kinjel Shah
Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.
Healthcare ETFs in Focus as Q3 Earnings Unfold
by Sweta Killa
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.
Stock Market News for Oct 27, 2021
by Zacks Equity Research
U.S. stocks continued their winning streak on Tuesday, with the Dow and the S&P 500 closing at record highs for the second straight day as investors digested a slew of earnings reports from some of biggest American corporations.
AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.
Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales
by Zacks Equity Research
Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.
Home Prices Stay "Lofty;" UPS Beats, Lilly Mixed
by Mark Vickery
The Case-Shiller Home Price Index for August came in at +19.8%, right in-line with what analysts were looking for.
Q3 Earnings Season in Full Swing
by Zacks Equity Research
Q3 Earnings Season in Full Swing
Eli Lilly (LLY) Misses Q3 Earnings Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of -2.02% and 1.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Glaxo (GSK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven third-quarter sales. Although sales of vaccines are likely to have recovered, the impact of the COVID-19 vaccine prioritization may have continued.
Gilead (GILD) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $243.75 in the latest trading session, marking a +1.07% move from the prior day.
Should You Buy Eli Lilly and Company (LLY) Ahead of Earnings?
by Zacks Equity Research
Eli Lilly and Company (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Teladoc Health's (TDOC) Earnings in Q3?
by Zacks Equity Research
Teladoc Health (TDOC) is likely to report a strong revenue outperformance for the third quarter, driven by broad-based momentum across its business and a sharp acceleration in visit-volume growth.
Radius (RDUS) Up On Positive Data From Breast Cancer Study
by Zacks Equity Research
Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.
Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib
by Zacks Equity Research
The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $237.88 in the latest trading session, marking a +0.5% move from the prior day.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FLQL
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL